2013
DOI: 10.3109/00365548.2012.755268
|View full text |Cite
|
Sign up to set email alerts
|

A severe case of Puumala hantavirus infection successfully treated with bradykinin receptor antagonist icatibant

Abstract: A patient with severe capillary leakage syndrome caused by a Puumala hantavirus infection was treated with a single dose of icatibant, a bradykinin receptor antagonist, with a dramatic positive response. We suggest that this drug should be tested in a larger number of patients with severe hantavirus infection.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

1
47
0
2

Year Published

2014
2014
2021
2021

Publication Types

Select...
8
1

Relationship

1
8

Authors

Journals

citations
Cited by 60 publications
(50 citation statements)
references
References 14 publications
1
47
0
2
Order By: Relevance
“…Interferon and replication inhibitors are efficacious prophylactically but not in viremic or symptomatic patients (5, 21, 98). However, one Puumala virus patient recovered after being given a dose of the bradykinin antagonist icatibant (90) and this supports a role for bradykinin in HFRS pathogenesis (39). However, further studies are needed to determine if icatibant or several additional therapeutics provided to the patient played a key role in recovery (90).…”
Section: Discussionmentioning
confidence: 80%
See 1 more Smart Citation
“…Interferon and replication inhibitors are efficacious prophylactically but not in viremic or symptomatic patients (5, 21, 98). However, one Puumala virus patient recovered after being given a dose of the bradykinin antagonist icatibant (90) and this supports a role for bradykinin in HFRS pathogenesis (39). However, further studies are needed to determine if icatibant or several additional therapeutics provided to the patient played a key role in recovery (90).…”
Section: Discussionmentioning
confidence: 80%
“…In fact even inapparent cellular stresses like breathing-directed cyclic stretching of the pulmonary endothelium (88, 89) may contribute to capillary leakage when uncoupled from normal MEC integrity. The cause of vascular leakage during hantavirus diseases has been speculated to stem from a wide range of effectors, including growth factors, kinins, immune responses, cytokines, T cells, and permeability factors (1820, 29, 31, 32, 35, 36, 39, 77, 90). Although several factors are likely to contribute to permeability, immunosuppression of HV patients has no effect on the disease (21) and recent findings suggest that immune responses are not determinants of vascular leakage in animal models of ANDV infection (13, 22, 23).…”
Section: Discussionmentioning
confidence: 99%
“…The pathogenesis of this has not been fully elucidated, but it may involve the release of bradykinin, which increases vascular permeability in various pathological conditions. Indeed, the selective bradykinin type 2 receptor antagonist, icatibant, was successfully administered in 2 cases of life-threatening PUUV infection [48,49] . In imaging studies of PUUV-infected patients, signs of fluid accumulation and edema have been frequently found [50] .…”
Section: Discussionmentioning
confidence: 99%
“…• Vascular leakage is described for virtually all forms of Hantavirus infection, and while the mechanism remains unknown, it is believed to involve inflammatory immune responses. • Presently, treatment options for NE as well as other Hantavirus-associated pathologies are limited [46,47]. For these reasons, future studies into the inflammatory mechanism of hantavirus infection will lead to greater understanding of disease pathogenesis and, in turn, may lead to improved treatment strategies and options for healthcare practitioners.…”
Section: Conclusion and Future Perspectivementioning
confidence: 99%